Clinical Trial Update: Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB [Phase 2]

View source ↗

Summary

Phase 2 open-label randomized trial comparing Entresto against calcium channel blockers/ARBs for chronic severe aortic valve insufficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Valve Insufficiency

Drugs mentioned

• Entresto (sacubitril/valsartan)

Snippet

Sponsor: Samsung Medical Center | Conditions: Aortic Valve Insufficiency | Phase 2 | Status: UNKNOWN